CD8+ T lymphocytes infiltrating breast cancer: A promising new prognostic marker? by Mahmoud, Sahar et al.
CD8
+ T lymphocytes infiltrating breast cancer




1,3 and Andrew R. Green
1,*
1Division of Pathology; School of Molecular Medical Sciences; University of Nottingham; Nottingham, UK;
2Clinical Pathology Department; Faculty of Medicine; Mansoura
University; Mansoura, Egypt;
3Department of Histopathology; Nottingham University Hospitals NHS Trust; Nottingham, UK
Keywords: CD8, breast cancer, immunosurveillance, immunohistochemistry, tissue microarrays
Lymphocytic infiltration is often seen in breast cancer and has been suggested as a marker of host anti-tumor response
but its importance in prognosis remains controversial. Our recent study demonstrated an association between tumor-
infiltrating CD8
+ T lymphocytes in invasive breast cancer and better prognosis.
Understanding the role of immune system
in cancer development and progression has
been one of the most challenging ques-
tions in immunology. The formulation
of the cancer immunoediting hypothesis
not only indicates a role for the immune
system in the active elimination of
immunogenic tumor cells (immunosur-
veillance), but also emphasizes the import-
ance of immunity in promoting the
outgrowth of less immunogenic tumor cell
variants.
1 Breast cancer is a major health
problem for women worldwide with more
than one million cases are diagnosed every
year. The efficacy of current treatment is
limited by inherent therapeutic resistance
and by collateral damage to normal tissues
which highlights the need for new highly
targeted therapeutic approaches. Infiltra-
tion of immune cells is a well-documented
observation in breast carcinoma. However,
the role of the immune response in
patients with breast cancer is still a source
of controversy with regards to its relation-
ship with patient outcome. We analyzed a
cohort of 1334 unselected breast tumors
from patients with long-term follow-up for
the density and micro-anatomical local-
ization of CD8
+ cytotoxic T lymphocytes
using tissue microarrays and immuno-
histochemistry.
2 High numbers of CD8
+
cells infiltrating carcinomas were signifi-
cantly correlated with high histological
grade, younger patient age and negative
estrogen receptor status. High CD8
+ cell
counts were associated with improved
patient outcome (Fig.1), independent of
the standard prognostic and predictive
factors.
2
These data indicate that a stratification
of the patients based on the assessment of
CD8
+ cell density could be of interest in
clinical practise. Importantly, this method-
ology uses a routine immunohistochemi-
stry and commercially available antibody to
detect a marker that may potentially
increase prediction accuracy of assessment
of patient prognosis for planning of appro-
priate adjuvant therapy. Previous studies
examining other types of cancer have
reached a similar conclusion.
3,4 Indeed,
assessment of inflammation is recom-
mended for melanoma, Markel cell carcin-
oma and colorectal carcinoma.
5 The results
of these studies provide evidence for the
equilibrium phase of cancer immunoedit-
ing in humans. In the equilibrium phase of
cancer immunoediting process, the adap-
tiveimmunesystem preventstumorgrowth
and also sculpts the immunogenicity of the
tumor cells.
1 However, breast cancer is a
heterogeneous disease with different types
having remarkably different biological
characteristics and clinical behavior. Not
all the results on the role of inflammatory
cells in breast cancer are consistent.
Another study with similar design to ours
found CD8
+ cells were of independent
value only in estrogen receptor negative
carcinomas.
6 Similar results have been
found using microarray gene expression
data.
7 Our data showed that the CD8
+ cell
density was not of prognostic value in
patients with HER2 positive carcinomas,
2
but others have found an association
between immune genes and better prog-
nosis in this tumor type.
8 It is likely that
different immune mechanisms are import-
ant in different types of breast cancer and
this deserves further investigation. Also
there is evidence that other components
of immune response, such as B cells, are
important in breast cancer.
9
The role of tumor infiltrating leukocytes
in cancer formation and progression
has been considered one of hallmarks
of cancer.
10 Hence, harnessing tumor-
immune/inflammation interaction has
become an important focus of anti-cancer
research with the development of tumor
vaccines and immune modulating ther-
apies. Given the evidence discussed in this
article, the hypothesis that adaptive
immunity is implicated in breast cancer
prognosis deserves consideration and fur-
ther investigation. Although early results
of immunotherapy in breast cancer have
been disappointing, the finding of an
association between CD8
+ count and
better prognosis in our study suggest that
further investigation of this mode of
treatment should be encouraged.
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Figure1. Kaplan-Meier curves of breast cancer specific survival (BCSS) for CD8
+ lymphocytic infiltration in the training set. (A) Survival curve for the total
number of CD8
+ lymphocytes, (B) Survival curve for the distant stromal CD8
+ lymphocytes.
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